In hepatocarcinoma cells (HCC), metformin inhibited phosphofructokinase-1 (PFK1) activity by suppressing the expression of PFK2, thereby reducing the allosteric activation of PFK1 by fructose-2,6-bisphosphate [46] (Figure 1). The gene discussed is PFKM; the disease is hepatocellular carcinoma.